May 5th 2021
By Tony Hagen
The anatomy of an interchangeability switching study.
May 4th 2021
Amgevita is now broadly available across Canada.
By Skylar Jeremias
Biosimilar companies partnered with other companies and saw earnings increases, while reference product corporations faced sales erosion from biosimilar competition.
May 3rd 2021
Representative Carolyn B. Maloney, D-New York, questions the use of pharmaceutical profits to defend against biosimilar competition.
April 30th 2021
There's no end in sight for Enbrel (etanercept) sales erosion, but Amgen's biosimilars are holding their own, the company reported.
April 29th 2021
The results of Voltaire-X could persuade the FDA to authorize automatic substitution of the adalimumab biosimilar Cyltezo for its reference product (Humira), investigators believe.
April 28th 2021
How much muscle did Congress invest in a pair of bills recently signed by President Biden? The answer may lie in your willingness to believe.
April 24th 2021
Medicinal packaging shouldn't remind patients that they have a condition, according to Samsung Bioepis.
April 23rd 2021
The European Union is a diverse market with pockets of biosimilar resistance but also cost-saving triumphs, panelists said at the Biosimilar Medicines Virtual Summit 2021.
April 19th 2021
Anticipating roughly $26 million in annual savings, British Columbia's public payer PharmaCare is switching patients away from originator Humira.
